Survival in End-Stage Dementia Following Acute Illness
JAMA 284: 47-52, 87, Morrison,R.S. & Siu,A.L., 2000
Treating Nondementia Illnesses in Patients With Dementia
JAMA 283:3230-3235, Brauner,D.J. et al, 2000
Patterns of Brain Activation in People at Risk for Alzheimer's Disease
NEJM 343:450-456,502, Bookheimer,S.Y. et al, 2000
Relation Between Cholinesterase Inhibitor and Pisa Syndrome
Lancet 355:2222, Kwak,Y.T. et al, 2000
Immunization for Alzheimer's Disease: A Shot in the Arm or a Whiff?
Ann Neurol 48:553-555, Levey,A.I., 2000
Anti-Inflammatory Drugs Protect Against Alzheimer Disease at Low Doses
Arch Neurol 57:1586-1591, Broe,G.A.,et al, 2000
Treatment of Agitation in AD
Neurol 55:1271-1278,1247, Teri,L.,et al, 2000
Rivastigmine (Exelon) for Alzheimer's Disease
The Medical Letter 42:93-94, , 2000
The Value of Informant Versus Individual's Complaints of Memory Impairment in Early Dementia
Neurol 55:1724-1726, Carr,D.B.,et al, 2000
Screening for Dementia with the Memory Impairment Screen
Neurol 52:231-238,224, Buschke,H.,et al, 1999
Progressive Aphasia with Rapidly Progressive Dementia in a 49 Year Old Woman
JNNP 66:238-243, Greene,J.D.W.,et al,, 1999
Efficacy and Safety of Rivastigmine in Patients with Alzheimer's Disease:International Randomised Controlled
BMJ 318:633-640, 615, Rosler,M.,et al, 1999
Mild Cognitive Impairment, Clinical Characterization and Outcome
Arch Neurol 56:303-308, Petersen,R.C.,et al, 1999
Ethnic Difference in Incidence of Stroke:Prospective Study with Stroke Register
BMJ 318:967-971, Stewart,J.A.,et al, 1999
Diagnosis, Management, and Treatment of Alzheimer Disease, A Guide for the Internist
Arch Int Med 159:789-798, Richards,S.S.&Hendrie,H.C., 1999
Cost-Effectiveness of Donepezil in the Treatment of Mild or Moderate Alzheimer's Disease
Neurol 52:1138-1145,1115, Neumann,P,J.,et al, 1999
Clinicopath Conf:Multisystem Neurodegenerative Disease with Dementia Pugilistica
NEJM 340:1269-1277, Case 12-1999, 1999
Reye's Syndrome in the United States from 1981 Through 1997
NEJM 340:1377-1382,1423, Belay,E.D.,et al, 1999
Medial Temporal Lobe Atrophy on MRI in Dementia with Lewy Bodies
Neurol 52:1153-1158, Barber,R.,et al, 1999
Do We Have Drugs for Dementia? No
Arch Neurol 56:735-737, Pryse-Phillips,W., 1999
Do We Have a Treatment for Alzheimer Disease? Yes
Arch Neurol 56:738-739,735, Gauthier,S., 1999
Serial Magnetic Resonance Imaging of Cerebral Atrophy in Preclinical Alzheimer's Disease
Lancet 353:2125, Fox,N.C.,et al, 1999
Variability in Annual Mini-Mental State Examination Score in Patients with Probable Alzheimer Disease
Arch Neurol 56:857-862, Clark,C.M.,et al, 1999
Molecular Basis of the Neurodegenerative Disorders
NEJM 340:1970-1980, Martin,J.B., 1999
Prethrombotic Disorders in Children with Arterial Ischemic Stroke and Sinovenous Thrombosis
Arch Neurol 56:967-971, Bonduel,M.,et al, 1999
A Randomized Trial of Risperidone,Placebo,and Haloperidol for Behavioral Symptoms of Dementia
Neurol 53:946-955,899, DeDeyn,P.P.,et al, 1999
Clinical Benefits of Donepezil:Results from a Long-Term Phase III Extension Trial
Neurol 52:A174, Doody,R.S.,et al, 1999
Altered Brain Activation in Cognitively Intact Individuals at High Risk for Alzheimer's Disease
Neurol 53:1391-1396, Smith,C.D.,et al, 1999
Nuclear Medicine in Neurology and Psychiatry
Lancet 354:1107-1111, Costa,D.C.,et al, 1999
Sorting Out Sleep in Patients with Alzheimer's Disease
Lancet 354:2098-2099, Foley,D., 1999
Treatment of Alzheimer's Disease
NEJM 341:1670-1679, Mayeux,R.&Sano,M, 1999
Immunologic Treatment of Alzheimer's Disease
NEJM 341:1694-1695, Blass,J.P., 1999
Estrogen Use and Early Onset Alzheimer's Disease:A Population-Based Study
JNNP 67:779-781, Slooter,A.J.C.,et al, 1999
Functional Magnetic Resonance Imaging in Neuropsychiatry
BMJ 319:1551-1554, Longworth,C.,et al, 1999
Utility of the Apolipoprotein E Genotype in the Diagnosis of Alzheimer's Disease
NEJM 338:506-511, Mayeux,R.,et al, 1998
The APOE-e4 Allele and the Risk of Alzheimer Disease Among AFrican Americans, Whites and Hispanics
JAMA 279:751-755, 7881998., Tang,M.,et al, 1998
Estrogen Therapy in Postmenopausal Women, Effects on Cognitive Function and Dementia
JAMA 279:688-695, Yaffe,K.,et al, 1998
Neurology and the Blood:Haematological Abnormalities in Ischaemic Stroke
JNNP 64:150-159, Markus,H.S.&Hambley,H., 1998
Incidence of Status Epilepticus in Rochester, Minnesota, 1965-1984
Neurol 50:735-741, Hesdorffer,D.C.,et al, 1998
Epilepsy in Young People:23 Year Follow Up of the British National Child Development Study
BMJ 316:339-342, Kurtz,Z.,et al, 1998
Illicit Drug-Associated Ischemic Stroke in the Baltimore-Washington Young Stroke Study
Neurol 50:1688-1693, Sloan,M.A.,et al, 1998
Progression of Alzheimer's Disease in Black and White Patients
Neurol 51:154-158, Fillenbaum,G.G.,et al, 1998
Lack of Relation Between Race and Cognitive Test Performance in Alzheimer's Disease
Neurol 50:1499-1501, Carlson,M.G.,et al, 1998
Genetic Studies on Chromosome 12 in Late-Onset Alzheimer Disease
JAMA 280:619-622, 6521998., Wu,W.S.,et al, 1998
Evidence for an Alzheimer Disease Susceptability Locus on Chromosome 12 and for Further Locus Heterogeneity
JAMA 280:614-618, 6521998., Rogaeva,E.,et al, 1998
Pharmacologic Treatment of Cognition in Alzheimer's Dementia
Neurol 51:S36-S44, Farlow,M.R.&Evans,R.M., 1998
Donepezil Improves Cognition & Global Function in Alzheimer Dis, 15-Week Doub-Blind, Plac-Contr Study
Arch Int Med 158:1021-1031, 9411998., Rogers,S.L.,et al, 1998
Is Exposure to Aluminum a Risk Factor for the Development of Alzheimer Disease? -Yes
Neurol 55:740-742, Forbes,W.F.&Hill,G.B., 1998
Is Exposure to Aluminum a Risk Factor for the Development of Alzheimer Disease? -No
Arch Neurol 55:737-739, 7421998., Munoz,D.G., 1998
Preclinical Prediction of Alzheimer's Disease Using SPECT
Neurol 50:1563-1571, Johnson,K.A.,et al, 1998